Search

DNA hypermethylation is one of the most common epigenetic modifications in prostate cancer (PCa). Several studies have delineated sarcosine as a PCa oncometabolite that increases the migration of malignant prostate cells while decreasing their doubling time. Here, we show that incubation of prostate cells with sarcosine elicited the upregulation of sarcosine N‐demethylation enzymes, sarcosine dehydrogenase and pipecolic acid oxidase. This process was accompanied by a considerable increase in the production of the major methyl‐donor S‐adenosylmethionine (SAMe), together with an elevation of cellular methylation potential. Global DNA methylation analyses revealed increases in methylated CpG islands in distinct prostate cell lines incubated with sarcosine, but not in cells of nonprostate origin. This phenomenon was further associated with marked upregulation of DNA methyltransferases (Dnmts). Epigenetic changes were recapitulated through blunting of Dnmts using the hypomethylating agent 5‐azacytidine, which was able to inhibit sarcosine‐induced migration of prostate cells. Moreover, spatial mapping revealed concomitant increases in sarcosine, SAMe and Dnmt1 in histologically confirmed malignant prostate tissue, but not in adjacent or nonmalignant tissue, which is in line with the obtained in vitro data. In summary, we show here for the first time that sarcosine acts as an epigenetic modifier of prostate cells and that this may contribute to its oncometabolic role. [ABSTRACT FROM AUTHOR]

To date, there has been no evidence regarding the association between urinary sarcosine content and prostate cancer survival. Our main objective was to investigate whether levels of post‐treatment urinary sarcosine are associated with relapse. The inclusion criteria were (in accordance with EAU 2017) as follows: histopathologically verified adenocarcinoma in prostate biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE) with retained ability to urinate. The median follow‐up was 53 months. In the study, we retrospectively evaluated a cohort of 511 patients with prostate cancer with various risk factors and treatment strategies. Post‐treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (≥200 nmol/L) in 71 (13%) patients. Urinary sarcosine content was significantly associated with number of relapses that patients experienced, P = 0.002 for sarcosine ≥200 vs ≤30 nmol/L. Multivariate analysis revealed that sarcosine was an independent predictor of recurrent relapses (≥2 relapses with an intermediate period of remission), HR = 3.89 (95% CI 1.29‐11.7) for sarcosine >200 vs <30 nmol/L. This trend was even more pronounced in a subgroup of patients who underwent radical prostatectomy, HR = 3.29 (95% CI 1.06‐10.18), where (single) relapse‐free survival could also be predicted by sarcosine levels, HR = 1.96 (1.05‐3.66). Urinary sarcosine may become a possible predictor for patients' outcomes, because patients with elevated post‐treatment sarcosine could be predicted to have recurrent relapses of the disease. Risk of relapses is increased in prostate cancer patients with high post‐treatment urinary sarcosine, as shown by a retrospective study on 511 patients. [ABSTRACT FROM AUTHOR]

The current study aims at preparing biocompatible hybrid organic-inorganic ruthenium core-shell nanostructures (RuNPs) coated with polyvinylpyrrolidone (PVP) and polyoxyethylene stearate (POES). Thereafter, the core/shell RuNPs are loaded with doxorubicin (to form RuPDox) with a loading efficiency > 60%. RuPDox possesses exceptional stability and pH-responsive release kinetics with approx. 50% release of doxorubicin at up to 1 h exposure to an acidic endosomal environment. The cytotoxic effects of RuPDox are tested in vitro against breast cancer (MDA-MB-231), ovarian cancer (A2780), and neuroblastoma (UKF-NB-4) cells. Notably, although RuNPs have slight cytotoxicity only, RuPDox causes a synergistic enhancement of cytotoxicity when compared to free doxorubicin. Significant increase in free radicals formation, enhanced activity of executioner caspases 3/7, and higher expression of p53 and metallothionein is further identified due to the RuPDox treatment. Single-cell gel electrophoresis reveals no additional contribution of RuNPs to genotoxicity of doxorubicin. Moreover, RuPDox promotes significantly increased stability of doxorubicin in human plasma and pronounced hemocompatibility assayed on human red blood cells. The results imply a high potential of biocompatible hybrid RuNPs with PVP-POES shell as versatile nanoplatforms to enhance the efficiency of cancer treatment. [ABSTRACT FROM AUTHOR]

The correct TEM micrograph showing Dox-loaded RuPDox is shown below. B 2017 b , I 34 i , 1700289 DOI: 10.1002/ppsc.201700289 In this originally published article it was inadvertently used two adjacent transmission electron microscopy (TEM) micrographs, both showing non-loaded RuNPs (Figure 1D). PH-Responsive Hybrid Organic-Inorganic Ruthenium Nanoparticles for Controlled Release of Doxorubicin. [Extracted from the article]

Abnormal activity of the core cell-cycle machinery is seen in essentially all tumor types and represents a driving force of tumorigenesis. Recent studies revealed that cell-cycle proteins regulate a wide range of cellular functions, in addition to promoting cell division. With the clinical success of CDK4/6 inhibitors, it is becoming increasingly clear that targeting individual cell-cycle components may represent an effective anti-cancer strategy. Here, we discuss the potential of inhibiting different cell-cycle proteins for cancer therapy. [ABSTRACT FROM AUTHOR]

Recently, the interest is increasing to find alternatives to replace the usage of antibiotics since their massive and improper usage enhance the antibiotic resistance in human pathogens. In this study, for the first time we showed that the soil proteins have very high antibacterial activity (98% of growth inhibition) against methicillin resistant Staphylococcus aureus (MRSA), one of the most threatening human pathogens. We found that the protein extract (C3) from the forest with past intensive management showed higher antibacterial activity than that of unmanaged forest. The MIC and IC 50 were found to be 30 and 15.0 μg protein g−1 dry soil respectively. C3 was found to kill the bacteria by cell wall disruption and genotoxicity which was confirmed by optical and fluorescent microscopy and comet assay. According to qPCR study, the mecA (the antibiotic resistant gene) expression in MRSA was found to be down-regulated after C3 treatment. In contrast, C3 showed no hemolytic toxicity on human red blood cells which was confirmed by hemolytic assay. According to ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS), 144 proteins were identified in C3 among which the majority belonged to Gram negative bacteria (45.8%). Altogether, our results will help to develop novel, cost-effective, non-toxic and highly efficient antibacterial medicines from natural sources against antibiotic resistant infections. • Soil subjected to anthropogenic activities are hotspots for the pharmacological studies. • Soil proteins showed high antibacterial activity against MRSA. • They have multiple targets including bacterial cell wall and DNA. • Soil proteins are highly efficient, non-toxic and natural antibacterial compound. [ABSTRACT FROM AUTHOR]

• Biphasic (anatase-brookite) TiO 2 NPs were synthesized and tested. • Anatase-prevailing TiO 2 NPs induced more oxidative stress and DNA fragmentation. • Anatase-prevailing TiO 2 NPs deregulated proteome of benign epithelial cells. • Anatase crystalline phase contributes to overall cytotoxicity more than brookite. Nanoparticular form of titanium dioxide (TiO 2 NPs) belongs to important industrial material. Despite being widely used, serious contradictions regarding biosafety of TiO 2 NPs remain. We anticipate that such discrepancies could be due to a lack of understanding of a linkage between TiO 2 NPs phase composition and cytotoxicity. Therefore, we synthesized two types of biphasic TiO 2 NPs differing in an anatase-brookite phase composition. The study presents an array of in vitro data suggesting that TiO 2 NPs with a prevailing anatase phase composition possess higher cytotoxicity compared to TiO 2 NPs with an equal anatase-brookite crystallinity. This phenomenon was evidenced by significantly higher inhibition of metabolic activity and growth of epithelial and neuroblast-like cells. Moreover, anatase-prevailing TiO 2 NPs tend to produce higher amount of reactive oxygen species resulting in DNA fragmentation. Further insights into the molecular aspects of cytotoxicity of anatase-prevailing TiO 2 NPs were obtained by comparative proteomics delineating that TiO 2 NPs deregulate expression of a variety of proteins and associated pathways. This inevitably results in a decreased cellular ability to detoxify reactive oxygen species and respond to various stress conditions. The study provides novel data that add another piece to the jigsaw of the relation between structural features of NPs and biosafety. [ABSTRACT FROM AUTHOR]